Impairment of adenosinergic system in Rett syndrome: Novel therapeutic target to boost BDNF signalling.
Adenosinergic system
Brain-derived neurotrophic factor
Mecp2 knockout model
Rett syndrome
TrkB receptors
Journal
Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
21
04
2020
revised:
23
07
2020
accepted:
08
08
2020
pubmed:
18
8
2020
medline:
13
10
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
Rett syndrome (RTT; OMIM#312750) is mainly caused by mutations in the X-linked MECP2 gene (methyl-CpG-binding protein 2 gene; OMIM*300005), which leads to impairments in the brain-derived neurotrophic factor (BDNF) signalling. The boost of BDNF mediated effects would be a significant breakthrough but it has been hampered by the difficulty to administer BDNF to the central nervous system. Adenosine, an endogenous neuromodulator, may accomplish that role since through A
Identifiants
pubmed: 32798727
pii: S0969-9961(20)30318-1
doi: 10.1016/j.nbd.2020.105043
pii:
doi:
Substances chimiques
Brain-Derived Neurotrophic Factor
0
Mecp2 protein, mouse
0
Methyl-CpG-Binding Protein 2
0
Receptor, Adenosine A1
0
Receptor, Adenosine A2A
0
Receptor, trkB
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105043Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no competing interests.